Astellas Says Newer Drugs Set to Drive Profit Growth by 2030
Astellas Pharma Inc. will lean on high-margin brands like cancer drug Padcev and eye treatment Izervay to reach a five-year target of at least ¥4.3 trillion ($27 billion) in cumulative...
By Eru Ishikawa · Bloomberg
Astellas Pharma Inc. will lean on high-margin brands like cancer drug Padcev and eye treatment Izervay to reach a five-year target of at least ¥4.3 trillion ($27 billion) in cumulative core operating profit before R&D expenses.